Becton, Dickinson and Company logo BDX - Becton, Dickinson and Company

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 16
HOLD 17
SELL 1
STRONG
SELL
0
| PRICE TARGET: $177.00 DETAILS
HIGH: $204.00
LOW: $159.00
MEDIAN: $175.00
CONSENSUS: $177.00
UPSIDE: 10.67%

About Becton, Dickinson and Company (https://www.bd.com)

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Key Executives

NAME TITLE DOB SALARY
Thomas E. Polen Jr. President, Chief Executive Officer & Chairman 1973 $3,588,724 USD
Michael C. Feld Executive VP & Chief Revenue Officer 1981 $1,910,642 USD
Vitor Roque Executive Vice President & Chief Financial Officer 1983 $1,777,376 USD
Richard Byrd Executive Vice President & President of Interventional Segment 1968 $1,406,554 USD
Michael Garrison Executive VP & President of Medical Segment and BioPharma Systems Segments 1969 $1,360,526 USD
Carla Burigatto Senior Vice President & Chief Communications Officer
Denise Fleming Executive Vice President & Chief Information Officer 1971
Elizabeth McCombs Executive Vice President & Chief Technology Officer 1977
Joseph Smith Senior Vice President & Chief Scientific Officer
Lanesha T. Minnix Executive Vice President & General Counsel 1975
Meera Gopalakrishnan Senior VP & Global Chief Marketing Officer

Company Peers

Peer analysis pending, check back in 1-2 minutes.